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Introduction
Folic acid supplementation is widely prescribed to women 
of child-bearing age due to its determinative role in 
preventing most prevalent congenital anomalies and 
neuronal tube defects [1]. To increase the efficacy of folic 
acid supplementation, fortification of staple foods with 
folic acid has also been legislated in numerous states 
across the world [2]. As a consequence, overloads of folate 
in body have been demonstrated by epidemiological 
studies [3, 4], raising concerns given the possible role of 
folic acid in colorectal cancer promotion by stimulating 
precancerous cell growth if administrated in early stages 
of cancer [5].
Findings on folic acid/folate intake and colorectal 
cancer among nations with different ethnicities and 
lifestyles are inconclusive [6]. While a large investigation 
of 10 European countries, as well as those from US and 
Japanese populations, did not support an association 
between plasma folate and risk of colorectal cancer [7–9], 
one study on women residing across the US demon-
strated a highly protective effect of high folate levels in 
blood [10]. Other studies conducted among Chinese and 
Swedish people reported an adverse effect of high folate 
levels in blood on the risk of colorectal cancer [11–13]. 
In our previous investigation, we found no effect of folic 
acid supplementation on the risk of colorectal cancer in a 
meta-analysis of 35 studies [6]. The contraversies in find-
ings among different nations are partly due to applied 
methods in assessing folic acid effects, such as measuring 
red blood cell folate, or plasma folate, or total folate intake 
[6], or variation in ethnicity and life style [14]. Further, 
given the findings are mainly from developed nations and 
the data from developing regions who have different life-
styles, and that environmental and genetic background 
are neglected, it is crucial to have corresponding evidence 
from less represented regions with different ethnicities. 
Given the controversies and lack of evidence from devel-
oping nations with less represented ethnicities, we aimed 
to investigate the effects of folic acid supplementation 
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Z. Alizadeh* and Geertruida H. de Bock*
Background: An ongoing controversy exists on the role of folic acid supplementation in colorectal cancer 
risk among epidemiological studies. 
Objective: To assess the association between maternal folic acid supplementation and colorectal cancer 
risk.
Methods: A paired matched case control study of 405 subjects was performed, including women residing in 
135 villages of East Azerbaijan, Iran. Per area, subjects were followed regularly in local healthcare centers, 
where health- and social-related information have been collected prospectively in face to face interviews 
by well-trained health workers. We extracted folic acid supplement intake, baseline characteristics, and 
confounders from healthcare records. The data for study participants were linked to national cancer 
registry repositories, from which we retrieved the data of 135 women diagnosed with colorectal cancer 
between 2005 to 2015. Two hundred seventy controls were individually matched with cases in terms of 
residing village, age, and gender. We applied multivariate conditional logistic regression to estimate odds 
ratios (ORs) and 95% confidence intervals (CIs). 
Findings: There was no significant association between folic acid supplementation and colorectal cancer 
risk in those with history of folic acid intake compared to those with no history of intake (OR 0.95; 95% 
CI 0.59 to 1.53), in those with less than five years of folic acid (0.79; 0.45 to 1.39) or in those with ≥5 
years intake (1.09; 0.52 to 2.26). This risk did not change after adjustment for covariates or further 
stratification. 
Conclusions: Maternal folic acid supplementation did not affect colorectal cancer risk in a population 
where supplemental folic acid is prescribed with regular intervals for women of child-bearing age.
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on the risk of colorectal cancer in an ethnically homog-
enous Turkish-Azari population, who were followed for a 
long time during and after the history of use of folic acid 
supplementation.
Methods
In a paired matched case-control design, the association 
between folic acid supplementation intake and colorectal 
cancer risk in women was assessed. 
Setting
The study was performed in rural parts of East Azerbaijan, 
Iran. The area was chosen due to its having a mono ethnic 
background, mostly identical lifestyle, and the fact that 
the study province is among the regions with high rates of 
colorectal cancer (with an age standard rate of 13.32 per 
100,000 in women, compared to a lower 5.34 per 100,000 
incidence rate among women residing in other provinces 
of the country). These factors, combined with rigorous 
implementation of folic acid supplementation, make the 
population of this province suitable for investigating the 
effect of folic acid supplementation on colorectal cancer 
[15, 16]. The detailed health data of women residing in 
rural areas are constantly recorded by well-trained health 
workers in local health, including the data related to 
antenatal, perinatal, and postnatal care, and supplemen-
tation and medical history. 
Population 
The study population was selected from women residing 
in entirely rural parts of East Azerbaijan province, Iran. A 
total of 178,867 women of 40–80 years age live in rural 
parts of this province. The cases and controls recruit-
ment process is depicted in Figure 1. Pathologically 
confirmed colorectal cancer cases, according to ICD-OC 
153.0–153.9 for colon and 154.0–154.8 for rectal cancer, 
diagnosed between 2004 and 2015, were identified from 
the National Cancer Registry repositories, using the link-
ing identification numbers. Completeness of coverage 
was measured as the number of reported cases of cancer 
per year divided by the number of gastrointestinal tract 
cancers in Iran estimated by the WHO [17]. This demon-
strated a 60–70% coverage of all cancer cases [18]. We 
identified 161 women who were diagnosed as having 
colorectal cancer. Twenty-six cases were excluded due to 
incorrect international disease classification coding in 
the cancer registry. Given the possibility of missed cases 
due to systematic errors or insufficient coverage of the 
cancer registry, the pathological records of all cancerous 
patient colorectal cancer among study participants. Using 
systematic random sampling methods for each case from 
the same village, two controls were selected who were 
alive and had not been diagnosed with any type of cancer. 
Controls were matched to cases based on residing village, 
age (within a range of 4 years), and sex. The protocol of 
Figure 1: Study Flow chart.
Abbreviations: CRC: Colorectal cancer, EA: East Azerbaijan, GP: General practitioner.
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the study was according to the Helsinki Declaration and 
was approved by ethical committee of Tabriz University 
of Medical sciences, Iran (Reference number: TBZMED.
REC.1394.1193).
Data collection
The data collection was based on registered data of folic 
acid supplement intake in health centers in villages. The 
dose of folic acid for supplementation was 2.8 mg/wk or 
0.4 mg/day. The supplementation dosage and duration is 
explained in WHO guidelines [19]. Folic acid supplements 
are regularly prescribed for women of child-bearing age 
since past 12 years in villages. The supplement intake was 
not mandatory, and unconsumed supplements or refusal 
to take the supplements was recorded. This routine prac-
tice is implemented across the entire country using a 
structured data collection by digital method. Inhabitants 
of these regions are regularly visited, and detailed health 
related information on medications (including supple-
ment intakes) and health status have been continuously 
recorded by well-trained health workers since 1991. Basic 
demographic data and certain lifestyle data assessments are 
recorded, including every prescription issued by the general 
practitioner, all consultations with the general practitioner, 
test results, diagnoses from primary and secondary care, 
and referrals to outpatient clinics, hospital admissions, 
and deaths. The data from cases and control health docu-
ments includes height, weight 5 years before cancer diag-
nosis, supplement intake, education, and marital status. 
Also included were lifestyle factors, such as smoking, physi-
cal activity, co-morbidities, medicine intake history, and 
duration of supplement intake, and were extracted using 
a structured questionnaire. In the data extraction process, 
one investigator (SM) was responsible for extracting the 
data from the digital healthcare system. The accuracy of 
extracted data was checked by a second investigator (RD). In 
the case of discrepancies, the main document was checked 
in the presence of a third author (MA).
Data Analysis
Cases and controls were described regarding the charac-
teristics using a q square test. These characteristics were 
included in the study based on a review of the literature 
[10, 20]. The duration of data recording was calculated by 
the time period between the subjects’ initial recording 
date in the healthcare system and the date of cancer 
diagnosis for cases and their mached controls. We used 
conditional logistic regression using village and town level 
strata to estimate odds ratios (ORs) and 95% confidence 
intervals (CIs) for cancer in three subgroups of folic acid 
supplement intake (no history of intake, less than five 
years intake and more than five years intake) and for two 
tumor sites subgroups (colon and rectum). Using an eval-
uation test, the variables which modified the estimated 
risk for colorectal cancer by >%10 were identified. In the 
next step, in a multi-variate model, the estimated ORs for 
colorectal cancer in subgroups of folic acid supplement 
intake were adjusted for variables, including: smoking, 
body mass index, hypertension, diabetes, and GI disor-
ders. In the next step, in order to assess the effect of time 
between folic acid intake and colorectal cancer incidence, 
the analysis was restricted to folic acid intake at least 36 
months before the date of colorectal cancer diagnosis. 
Next, complete case analysis was performed by includ-
ing cases and controls with complete data on adjusting 
variables in multivariate analyses. We conducted analyses 
stratified by factors that previously have been reported 
to affect or modify the association between folate intake 
and colorectal cancer risk, including age group defined 
into two groups (40–49 years and ≥50 years); history of 
vitamin D supplement intake defined as no intake versus 
history of intake; GI discomfort defined as no history of GI 
discomfort and history of GI discomfort; and hypertension 
history with no history of hypertension versus a history 
of hypertension. Data analysis was done using the clogit 
command of the survival package in R version 3.5.1.
Results
The study population included 135 women with colorectal 
cancer and a total of 270 matched controls. See Table 1 
and Supplementary Table S1 for characteristics of the 
study population. Overall, cases had a mean age at diag-
nosis of 62.00 (SD 13.74) years. The cases were more likely 
to have a history of other GI disorders than were their 
matched controls (21.50% in cases compared to 9.60% in 
controls), whereas smoking status was similar for cases and 
controls. 23.70% of the study population (23.00% of cases 
and 24.10% of controls) had a history of folic acid intake in 
the past (Table 1). The mean observation period was iden-
tical for cases and their matched controls, and the mean 
duration of prospective data recording was 30.7 years (SD 
12.57). The registered mean duration using folic acid sup-
plement intake was 1.91 years (1.82 SD) in total, and for 
those users with more than five years, it was 5.8 years (1.59 
SD). For the large majority of cases with folic acid supple-
ment intake, the first intake within the follow-up period 
was at least 36 months before the data collection (87.10% 
cases; 93.80% controls). There was no significant associa-
tion between folic acid supplementation and colorectal 
cancer risk (OR 0.95, 95% CI 0.59–1.53) for those with his-
tory of folic acid intake compared to no history of intake. 
The decreased risk of colorectal cancer in folic acid intake 
for less than 5 years was not significant (0.79; 0.45 to 1.39). 
The increased risk for colorectal cancer in using folic acid 
for longer than five years was not significant (1.09; 0.52 to 
2.26). Folic acid intake was associated with 1.28 (0.70 to 
2.14) times increase in risk of colon cancer and 1.42 (0.65 to 
3.03) times decrease in rectal cancer. None of the observed 
results were significant (Table 2). Multivariate analysis and 
restricting analysis to history of intake to over 36 months 
since diagnosis showed minimal effects on estimated risk 
for colorectal cancer (Table 3). Associated risk also did not 
vary significantly between groups of patients stratified by 
age, history of vitamin D intake, gastro-intestinal disorders, 
smoking status, and hypertension (Figure 2). 
Discussion
Maternal folic acid supplementation did not adversely 
affect colorectal cancer risk in a population where sup-
plemental folic acid is regularly prescribed for women of 
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Table 1: Baseline characteristic of study population, all variables stated as N(%)1.
Characteristics2 Cases (n = 135) Controls (270) P-value




















Folic acid supplement intake 0.52
No intake 101(74.8) 204(75.5)
In past 31(23.0) 65(24.1)
<5 years intake 21(15.6) 51(18.8)
≥5 years intake 10 (7.4) 14(5.2)
Family history of cancer 0.11
No 98(74.8) 220(81.8)
Yes 33(25.2) 49(18.2)
Hypertension 33(24.4) 121(44.8) 0.00
Diabetes 10(7.4) 19(7.0) 0.89
GI discomfort 29(21.5) 26(9.6) 0.00
History of change in weight4 0.00
Yes 48(35.5) 22(10.37)
No 72(64.4) 242(89.6)
Vitamin D supplement intake 0.00
No history of intake 68(51.5) 46(17.0)
History of intake in past 64(48.5) 224(82.9)
<5 years intake 29(22.0) 40(14.8)
≥5 years intake 35(26.5) 184(68.1)
1 Q square test was applied to obtain the results.
2 Missing values (n, %), BMI (3, 0.1), Physical activity (12, 3.0), Smoking (11, 2.7), Alcohol (11, 2.7), Folic acid supplement intake (4, 1.0), 
Family history of cancer (5, 1.2), Hypertension (12, 3.0), Vitamin D intake (3, 0.7).
3 Past alcohol intake was not applicable to any of the participants.
4 Defined as >10% change (both increase and decrease) in body weight within study period.
Abbreviations: BMI, body mass index; GI, gastrointestinal.
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child-bearing age and wheat flour is the staple food being 
fortified with this vitamin [21]. The stratification to the 
duration of supplementation and tumor site gave similar 
results. 
Findings from present naturalistic investigation of real 
world data are consistent with that of a recent meta-
analysis showing null effect of folic acid supplementa-
tion on colorectal cancer risk within five years follow-up. 
Figure 2: Odds ratio of colorectal cancer in cases with history of folic acid intake, compared with those with no history 
of intake, categorized by various factors.1
1 Results are from multivariate conditional logistic regression for study population stratified by corresponding variables. 
Results for current smoking subgroups were not present due to small numbers.
Table 2: Association between folic acid supplememnt intake and colorectal cancer risk1.
Folic acid Supplementation Cases/control (n) OR (95% CI)2
Intake status in past
No history of intake 101/204 ref.
History of folic acid intake 31/65 0.95 (0.59 to 1.53)
No history of intake 101/204 ref.
<5 yrs intake 21/51 0.79 (0.45 to 1.39)
≥5 yrs intake 10/14 1.09 (0.52 to 2.26)
Classification by tumour site
No history of intake 101/204 ref.
Colon (with history of folate intake) 23/65 1.28 (0.70 to 2.14)
Rectum (with history of folate intake)  8/65 0.71 (0.33 to1.53)
1 Adjusted for matching variables including age and villages.
2 Overall P-Value >0.05.
Table 3: Multivariate analyses comparing relative risks for colorectal cancer in relation to folic acid supplement intake, 




history of folic acid intake 
vs no intake
OR (95% CI)1
≥5 yrs folic acid intake vs 
no intake
All exposures recorded at least 36 
months since diagnosis
27/61 0.81 (0.46 to 1.42) 1.00 (0.3.7 to 2.65)
Restricted analysis to those with full 
information on adjusting variables
22/62 0.95 (0.51 to 1.79) 0.81 (0.32 to 2.05)
1 Adjusted for smoking, body mass index, hypertension, diabetes, GI disorders, Overall P-value >0.05.
Abbreviations: CI, Confidence interval.
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The results of 10 European countries, as well as that of 
Japanese and US populations, demonstrated no signifi-
cant effect of folate levels in blood on colorectal cancer 
risk [22, 23]. On the contrary, studies in Swedish, Korean, 
and Chinese populations found high blood levels of 
folate were associated with increased risk of colorectal 
cancer [20, 24]. These controversial findings, especially 
from East Asian populations, may support the role of 
ethnicity, population-specific lifestyle, and dietary habits 
in modifying the effect of folate or folic acid intake on 
colorectal cancer risk. However, Gao et al. found protec-
tive effects of folic acid supplementation for three years 
on colorectal adenoma risk in the Chinese population 
[25]. It is worthwhile to note that subjects were patho-
logically confirmed to be free of any adenomas before 
the intervention, had lower baseline folate status, and 
had lower folic acid dosage prescribed (0.5 mg/week vs. 
2.8 mg/week for 39 months throughout pregnancy and 
weaning period, based on WHO guidelines). Although 
serum/plasma folate is a representative of folate/folic 
acid intake, it is not feasible to distinguish folate and 
folic acid using these biomarkers. Taking into account the 
difference between folate and folic acid metabolism in the 
body, and their effect on colorectal cancer, it is crucial to 
assess the findings on folate status with caution. 
It is worthwhile to note that folic acid supplementation 
in the present study was implemented in specific inter-
vals, which in turn impeded excess folic acid intake. From 
a pathological view, excess folate might lead to carcino-
genesis through pre-cancerous cellular replication, tumor 
genesis activation, and natural cell killers inhibition 
due to the crucial role of folate in methylation [26]. The 
adverse effect of excessive folic acid intake gets intensified 
in colorectal cancer because of high replication rates in 
colorectal epithelial cells and higher folate absorption, 
likewise due to excess folate production by colorectal 
microbes [27]. As a support of the latter, Cole et al., in a 
trial in the US [28], reported an adverse effect of folic acid 
supplementation for seven years on colorectal adenoma 
recurrence. Consequently, supplementation—with dos-
age and intervals recommended by WHO—for women of 
childbearing age might prevent the latter adverse effects. 
Given the long period of data collection time, the 
potential confounding variables were sufficiently followed 
up. Nevertheless, we studied the time interval between 
folic acid intake and colorectal cancer up to 36 months, 
and likewise the majority of studies had a short follow-up 
time. Since the plausible time interval between folic acid 
intake and incidence of colorectal cancer is proposed to 
be >10 years, further investigations with longer follow-up 
time are required to reveal any potential risk of folic acid 
supplementation on colorectal cancer in this population. 
Even though studies in the US population demonstrated 
beneficiary effects of high folate intake with time lag of 
>12 years [29], as well as that of high folate before and 
after fortification [30], scarce findings from other nations 
exist on the effect of folic acid supplementation with 
plausible time lag. Another issue is that in our study, 
limited cases had history of folic acid supplement intake 
before the fortification period (5 cases). Consequently, it 
was not possible to investigate the association stratified 
for before and after fortification. 
This study is among the investigations assessing the 
association between folic acid supplement intake and 
colorectal cancer risk in developing nations. Due to 
local culture, we were not able to extract valid data for 
alcohol consumption, data on dietary fiber, or processed 
meat consumption. In addition, precise estimations of 
physical activity were not available for the study popula-
tion. Nonetheless, these factors are expected to be dis-
tributed evenly among the rural population, and thus 
between cases and their matched controls. Also, as our 
study population consisted of women from rural parts of 
a province with a very small percentage with history of 
smoking, it was not possible to assess the risk of folic acid 
supplementation in the smoking subgroup. Furthermore, 
we had a limited number of cases and were restricted to 
women, although all inhabitants of rural parts diagnosed 
with colorectal cancer were included. Men were excluded 
since the complete data regarding supplement intake was 
not recorded for them. Moreover, it was not possible to 
assess folate intake and folate levels in blood, and yet the 
database was unique, actively recording the data on sup-
plementation and other health related factors in women 
of child-bearing age. 
The findings of present investigation demonstrated that 
maternal folic acid supplementation did not adversely 
affect colorectal cancer risk in a population where supple-
mental folic acid is prescribed with regular intervals for 
women of child-bearing age.
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